Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Jazz Pharmaceuticals PLC (JAZZ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Jazz Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
175.90 +2.10    +1.21%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
176.47
+0.57
+0.32%
18:48:22 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  IE00B4Q5ZN47 
CUSIP:  00B4Q5ZN4
  • Volume: 1,196,993
  • Bid/Ask: 173.02 / 183.50
  • Day's Range: 173.45 - 180.39
Jazz Pharma 175.90 +2.10 +1.21%
Latest Release

May 04, 2021

EPS / Forecast

3.92 / 3.73

Revenue / Forecast

607.58M / 609.32M

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Aug 10, 2021 06/2021 -- /  3.89 -- /  701.18M
May 04, 2021 03/2021 3.92 /  3.73 607.58M /  609.32M
Feb 23, 2021 12/2020 4 /  4.24 665.52M /  638.84M
Nov 02, 2020 09/2020 4.31 /  4.08 600.89M /  577.62M
Aug 04, 2020 06/2020 3.71 /  3.11 562.44M /  503.21M
May 05, 2020 03/2020 0.45 /  0.64 534.73M /  544.56M
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

JAZZ Comments

Write your thoughts about Jazz Pharmaceuticals PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Zoran Labus
Zoran Labus Mar 25, 2021 11:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
Jesus Jerez
Jesus Jerez Feb 24, 2021 1:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Take into account the risks, page 44 of th eannual report: ""However, FDA confirmed that the clinical benefit of Zepzelca based on the results of the ATLANTIS Phase 3 clinical trial evaluating Zepzelca in combination with doxorubicin for relapsed SCLC did not provide sufficient verification and we and PharmaMar will therefore need to conduct one or more additional clinical trials of Zepzelca to confirm its clinical benefit. Our failure to do so could result in the withdrawal of approval of Zepzelca, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In any event, if we are unable to comply with our post-marketing obligations imposed as part of the marketing approvals in the U.S., the EU, or other European countries, our approval may be varied, suspended or revoked, product supply may be delayed and our sales of and revenues from our products could be materially adversely affected. ""
Rober Asensio
Rober Asensio Feb 15, 2021 1:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
PharmaMar's antiviral is 100 times more effective against Covid-19 than other treatments, reducing its viral load by almost 100%
Chema Gonzalvez
Chema Gonzalvez Oct 19, 2020 11:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
"The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
Chema Gonzalvez
Chema Gonzalvez Oct 19, 2020 11:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
"The evolution (of the trial) has been magnificent, no patient has died, all have been practically discharged ... and the side effects have been perfectly controlled. I believe that we are facing a very promising drug (Aplidin), a drug that could be the first to have antiviral activity, which could prevent many of the side effects, that inflammatory phase (of the COVID-19 disease) that unfortunately many patients die from". Dr. José Barberán. Infectious disease specialist at the HM Montepríncipe hospital in Madrid, Spain.
Miosecops cook
Miosecops cook Oct 19, 2020 11:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
on so ii would need samples plenty and ill make my rounds
Iscritto Iscritti
Iscritto Iscritti Aug 14, 2019 8:50AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I see it as a very good stock and see very good income statements but don't know the company.. any downsides about it ?
Wojtek Stefanowicz
Wojtek Stefanowicz Feb 20, 2019 3:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buying now
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email